ADAR1 Capital Management LLC Purchases 125,446 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

ADAR1 Capital Management LLC boosted its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 177.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 196,248 shares of the company's stock after acquiring an additional 125,446 shares during the quarter. ADAR1 Capital Management LLC owned about 0.36% of Fulcrum Therapeutics worth $922,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its holdings in shares of Fulcrum Therapeutics by 2.3% in the 4th quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock worth $667,000 after purchasing an additional 3,126 shares in the last quarter. American Century Companies Inc. grew its position in Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock worth $567,000 after buying an additional 6,770 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Fulcrum Therapeutics by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 34,264 shares of the company's stock valued at $161,000 after buying an additional 8,761 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Fulcrum Therapeutics by 74.9% during the 4th quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after acquiring an additional 13,057 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Fulcrum Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company's stock worth $4,716,000 after acquiring an additional 13,485 shares in the last quarter. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC traded up $0.06 during trading hours on Friday, hitting $2.69. 162,190 shares of the company's stock traded hands, compared to its average volume of 942,944. The stock's fifty day moving average price is $3.21 and its two-hundred day moving average price is $3.63. The firm has a market cap of $145.20 million, a P/E ratio of -8.68 and a beta of 2.13. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $8.63.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.